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338Objective: In the Randomized On/Off Bypass (ROOBY) Trial, the efficacy of on-pump versus off-pump cor-
onary artery bypass grafting was evaluated. This ROOBY Trial planned subanalysis compared the effects on
postbypass patient clinical outcomes and graft patency of endoscopic vein harvesting and open vein harvesting.
Methods: From April 2003 to April 2007, the technique used for saphenous vein graft harvesting was recorded
in 1471 cases. Of these, 894 patients (341 endoscopic harvest and 553 open harvest) also underwent coronary
angiography 1 year after coronary artery bypass grafting. Univariate and multivariable analyses were used to
compare patient outcomes in the endoscopic and open groups.
Results: Preoperative patient characteristics were statistically similar between the endoscopic and open groups.
Endoscopic vein harvest was used in 38% of the cases. There were no significant differences in both short-term
and 1-year composite outcomes between the endoscopic and open groups. For patients with 1-year catheteriza-
tion follow-up (n ¼ 894), the saphenous vein graft patency rate for the endoscopic group was lower than that in
the open harvest group (74.5% vs 85.2%, P<.0001), and the repeat revascularization rate was significantly
higher (6.7% vs 3.4%, P<.05). Multivariable regression documented no interaction effect between endoscopic
approach and off-pump treatment.
Conclusions: In the ROOBY Trial, endoscopic vein harvest was associated with lower 1-year saphenous vein
graft patency and higher 1-year revascularization rates, independent of the use of off-pump or on-pump cardiac
surgical approach. (J Thorac Cardiovasc Surg 2011;141:338-44)Earn CME credits at
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The Journal of Thoracic and Cardiovascular SurgSince the publication of the first clinical report on endo-
scopic greater saphenous vein (SVG) graft harvesting
(EVH) in 1996,1 EVH has increased in popularity to be-
come the preferred method of SVG harvesting in the United
States and is now a class IIa recommendation on the basis of
level B evidence.2 According to the Society of Thoracic
Surgeons’ National Database (www.sts.org), EVH was
used in 70% of coronary artery bypass grafting (CABG)
procedures in 2008.
A significant number of studies have demonstrated short-
term advantages of EVH, including less wound morbidity,
less pain, better cosmetic results, and improved patient satis-
faction relative to open greater SVG harvesting (OVH).3-7
More recently, long-term follow up of the Project of Ex-vivo
Vein Graft Engineering via Transfection IV trial (PREVENT
IV) showed worse outcomes with EVH.8,9 The rate of SVG
failure was significantly higher among those who underwent
EVH (46.7% vs 38.0 %; odds ratio, 1.45; 95% confidence
interval, 1.20–1.76). At 3 years, EVH was also associated
with a significantly higher combined rate of death,
myocardial infarction, or repeat revascularization (20.2% vs
17.4%; adjusted hazard ratio, 1.22; 95% confidence
interval, 1.01–1.47). Because of the potential implications of
the longer term impact on outcomes, the role of EVH is
currently the object of much controversy in the literature.10-12ery c February 2011
FIGURE 1. Enrollment, treatment, and follow-up. ROOBY, Randomized
On/Off Bypass Trial; SVG, saphenous vein graft; OVH, open greater saphe-
nous veingraft harvest;EVH, endoscopicgreater saphenous vein graft harvest.
Abbreviations and Acronyms
sCABG ¼ coronary artery bypass grafting
EPIC ¼ Evaluation of the PAS-Port in
Coronary Surgery [trial]
EVH ¼ endoscopic greater saphenous vein
graft harvest




¼ Project of Ex-vivo Vein Graft
Engineering via Transfection IV
[trial]
ROOBY ¼ Randomized On/Off Bypass [trial]
SVG ¼ saphenous vein graft
VA ¼ Veterans Affairs
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DThe results of the Randomized On/Off Bypass (ROOBY)
Trial were recently published.13 This planned subanalysis
of the ROOBY Trial examines clinical outcomes in
ROOBY Trial patients who underwent SVG harvest by en-
doscopic and open techniques. Specifically, the ROOBY tri-
al’s primary short-term and 1-year clinical composite
outcomes and graft patency are compared between patients
who underwent EVH and those who underwent OVH.
MATERIALS AND METHODS
Study Design
The ROOBYTrial was a randomized, controlled, single-blind study that
randomly allocated patients undergoing nonemergency CABG to off-pump
versus on-pump techniques at 18 participating Veterans Affairs (VA) Med-
ical Centers in the United States (ClinicalTrials.gov Identifier:
NCT00032630). The ROOBY study protocol, including this analysis,
was approved by each participating VA Medical Center’s institutional
review board and research and development office. Informed consent
was obtained for each patient.
Details of the ROOBY study design and inclusion and exclusion criteria
have been published previously.14 At the beginning of the study in 2002, the
technique used to harvest SVG was not recorded on the study forms. In
2003, in light of emerging interest with EVH, institutional review board ap-
proval was obtained at every site to revise the study forms to allow collec-
tion of this data. Surgeons were encouraged to use whichever harvesting
technique they preferred in a balanced fashion between off- and on-
pump arms.
Study End Points
The ROOBY Trial’s primary short-term end point was a composite of
death or major perioperative complication (reoperation, new mechanical
support, cardiac arrest, coma, stroke, or renal failure requiring dialysis)
occurring within 30 days after surgery or before hospital discharge, which-
ever was later. The 1-year composite outcome was composed of all-cause
mortality, repeat revascularization between 30 days to 1 year, or nonfatal
myocardial infarction between 30 days and 1 year. Graft patency was
determined by 1-year follow-up cardiac catheterizations overread by an an-
giographic core laboratory that was blinded to all treatment details (includ-
ing EVH vs OVH). FitzGibbon grading was used to score graft patency.15
For this analysis, overall graft patency (open vs occluded) and the propor-
tion of patients with at least 1 occluded SVG were evaluated.The Journal of Thoracic and CaSurgical Procedure
All CABG procedures were performed through a standard median ster-
notomy. The 18 ROOBY Trial VAMedical Centers represented in this sub-
study were as follows: Albuquerque, Asheville, Cleveland, Dallas, Denver,
Durham, Gainesville, Los Angeles, Miami, Milwaukee, New York, Palo
Alto, Pittsburgh, Portland, San Antonio, San Francisco, Tampa, and Wash-
ington. EVH was not performed at 5 centers. Within the VA Medical Cen-
ters that used EVH, the use rate (determined for the cases performed with at
least 1 SVG conduit placed) ranged from 1.5% to 100%. The quality of the
SVG was evaluated intraoperatively and graded as good, intermediate, or
poor by the surgeon.
Statistical Analysis
Continuous variables were reported as mean  SD, and categoric vari-
ables were reported as frequencies. For categoric variables, a 2-tailed
continuity-corrected c2 or Fisher’s Exact test was used for univariate anal-
ysis. The Student t test or the Mann–Whitney U test was used for continu-
ous variables according to distribution. Multivariable logistic regression
models were built to predict the dichotomous substudy outcomes of inter-
est. For these, the variables considered eligible for model entry included the
30-day operative mortality risk estimate (as a summary patient risk mea-
sure), an EVH indicator variable, an off-pump indicator variable, and an in-
teraction term for the combination of EVH and off-pump techniques. A
sensitivity analysis was performed to evaluate for a differential EVH versus
OVH impact for high-volume versus low-volume EVH centers.RESULTS
From February 2002 through April 2007, the ROOBY
Trial enrolled 2203 patients. Beginning in April 2003,rdiovascular Surgery c Volume 141, Number 2 339




(n ¼ 907) P value
Age (y, mean  SD) 63.0  8.0 62.6  8.4 .28
Male 563 (99.8%) 897 (98.9%) .06
Chronic obstructive
pulmonary disease
138 (24.5%) 168 (18.5%) .007
Cerebrovascular accident 49 (8.7%) 62 (6.8%) .22
Peripheral vascular disease 84 (14.9%) 129 (14.2%) .76
Diabetes 256 (45.4%) 408 (45.0%) .91
Hypertension 490 (86.9%) 801 (88.3%) .41
Hyperlipidemia 500 (89.0%) 791 (87.4%) .41
Renal insufficiency
(creatinine>1.5 mg/dL)
40 (7.1%) 80 (8.8%) .28
Left ventricular ejection fraction
<35% 30 (5.5%) 51 (5.7%) .50
35%–44% 58 (10.7%) 113 (12.7%)
>44% 455 (83.8%) 723 (81.5%)
Urgent status 81 (14.4%) 110 (12.1%) .23
No. of diseased vessels
1 20 (3.6%) 39 (4.3%) .44
2 157 (25.3%) 228 (25.3%)
3 383 (68.4%) 634 (70.4%)
On-pump versus off-pump 285:279 449:458 >.999
Data represent numbers of patients except as marked.
TABLE 2. Preoperative characteristics for patients with 1-year




(n ¼ 553) P value
Age (y, mean  SD) 62.2  7.5 61.9  7.9 .53
Male 341 (100%) 546 (98.7%) .05
Chronic obstructive
pulmonary disease
75 (22.0%) 97 (17.5%) .12
Cerebrovascular accident 22 (6.5%) 31 (5.6%) .66
Peripheral vascular disease 50 (14.7%) 64 (11.6%) .18
Diabetes 150 (44.0%) 239 (43.2%) .84
Hypertension 293 (85.9%) 477 (86.3%) .92
Hyperlipidemia 303 (89.4%) 479 (86.8%) .29
Renal insufficiency
(creatinine>1.5 mg/dL)
13 (3.8%) 31 (5.6%) .27
Left ventricular ejection fraction
<35% 16 (4.8%) 24 (4.4%) .91
35%–44% 34 (10.2%) 59 (10.9%)
>44% 283 (85.0%) 459 (84.7%)
Unknown 8 (2.3%) 11 (2.0%)
Urgent status 52 (15.2%) 71 (12.8%) .32
No. of diseased vessels
1 16 (4.7%) 25 (4.5%) .60
2 99 (29.2%) 145 (26.2%)
3 224 (66.1%) 383 (69.3%)
On-pump versus off-pump 166:175 269:284 >.999
Data represent numbers of patients except as marked.




(n ¼ 907) P value
30-d Mortality 2 (0.4%) 10 (1.1%) .15
Reoperation for bleeding 14 (2.5%) 22 (2.4%) >.999
Repeat bypass 3 (0.5%) 13 (1.4%) .13
Cardiac arrest 8 (1.4%) 13 (1.4%) >.999
Renal failure 0 (0.0%) 12 (1.3%) .005
Stroke 4 (0.7%) 10 (1.1%) .59
New mechanical support 2 (0.4%) 15 (1.7%) .02
30-d Composite end point* 26 (4.6%) 64 (7.1%) .06
Data represent numbers of patients. *Primary 30-day composite end point was death,
reoperation, repeat bypass, cardiac arrest, stroke, new mechanical support, or renal
failure requiring dialysis.
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Dprospective collection of data regarding SVG harvest tech-
nique was begun (Figure 1). A total of 1471 patients (564
EVH, 907 OVH) with SVG used as a bypass conduit had
the harvesting technique used recorded The 30-day com-
posite end point was known in all cases. One-year compos-
ite follow-up was determined for 96% of these patients (555
EVH, 859 OVH). Follow-up angiography was obtained for
894 subjects (341 EVH, 553 OVH).
For both the population of all patients with SVG harvest
approach recorded (n ¼ 1471) and the subset with 1-year
cardiac catheterization (n ¼ 894), the preoperative patient
characteristics were generally balanced between the EVH
and the OVH groups (Tables 1 and 2). Almost all patients
were male (99%), reflective of the VA cardiac surgical pa-
tient population. Sixty-eight percent of patients had 3-ves-
sel coronary artery disease, and approximately 83% of
patients had preserved left ventricular function. Fewer
than 15% of study patients required urgent surgery.
The quality of the harvested SVG was assessed as good
in 81.6% of EVH and 85.6% of OVH patients, intermediate
in 15.7% of EVH and 12.7% of OVH patients, and poor in
2.8% of EVH and 1.7% of OVH patients (difference not
significant).
For the short-term composite end point, there was no sig-
nificant difference between EVH and OVH groups (Tables 3
and 4). More OVH patients than EVH patients (1.3%) had
renal failure (1.3% vs 0.0%, P ¼ .01), and more OVH
patients needed new mechanical support (1.7% vs 0.4%,
P ¼ .02).340 The Journal of Thoracic and Cardiovascular SurgRegarding the 1-year composite outcome, there were no
differences between EVH and OVH groups (Tables 5 and
6). For the subgroup of patients with 1-year cardiac
catheterization studies, the rate repeat revascularization
was significantly higher in the EVH group than in the
OVH group (6.7% vs 3.4%, P< .05), whereas the rates
of nonfatal myocardial infarction and of death were
similar (Table 6). Only 2 of the 42 patients that needed re-
peat revascularization (4.8%) required reoperative CABG,
whereas the vast majority (40/42, 95.2%) required percuta-
neous coronary intervention.
Graft patency results in the subgroup of 894 patients with
follow-up angiography are detailed in Table 7. A mean ofery c February 2011
TABLE 4. Thirty-day outcomes for patients with 1-year




(n ¼ 553) P value
30-d Mortality 0 0 NA
Reoperation for bleeding 9 (2.6%) 9 (1.6%) .33
Repeat bypass 1 (0.3%) 2 (0.4%) >.999
Cardiac arrest 4 (1.2%) 4 (0.7%) .49
Renal failure 0 (0.0%) 3 (0.5%) .29
Stroke 1 (0.3%) 4 (0.7%) .65
New mechanical support 0 (0%) 4 (0.7%) .30
30-d Composite end point* 12 (3.5%) 24 (4.3%) .60
Data represent numbers of patients. NA, Not applicable. *Primary 30-day composite
end point was death, reoperation, repeat bypass, cardiac arrest, stroke, new mechan-
ical support, or renal failure requiring dialysis.






(n ¼ 553) P value
Revascularization 23 (6.7%) 19 (3.4%) .033
Myocardial infarction 6 (1.8%) 11 (2.0%) >.999
Death 1 (0.3%) 2 (0.4%) >.999
1-y Composite end point* 28 (8.2%) 27 (4.9%) .061
Data represent numbers of patients. *Primary 1-year composite end point was death
from any causewithin 1 year after surgery, myocardial infarction between 30 days and
1 year, or any revascularization procedure between 30 days and 1 year.
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SVGs were assessed for patency. The incidence of a patient
having 1 or more occluded SVGs on follow-up angiography
was 41.3% in the EVH group, compared with 28.0% in the
OVH group (P<.0001). Overall SVG patency in the EVH
group was 74.5%, which was significantly worse than the
85.2% rate in the OVH group (P<.0001).
According to multivariable regression analysis, EVHwas
not found to be an independent and statistically significant
predictor of the 1-year composite outcome when other fac-
tors were held constant. Further, no interaction was found
between the SVG harvesting technique (EVH vs OVH)
and the use of an on-pump versus off-pump approach (dif-
ference not significant). Additionally, sensitivity analysis
found no differential EVH versus OVH effect for high-
volume versus low-volume EVH centers.
DISCUSSION
Although it has been established that internal thoracic ar-
teries have clinical and patency advantages relative to
SVGs,16 SVG conduits are still commonly used during
CABG. EVH technique has been developed in an effort to
decrease the complications associated with OVH and has
been documented to reduce wound-related morbidity.6,7
For patients in the ROOBY Trial with EVH versus OVH
data captured, there were no major differences found in the
ROOBY Trial’s primary short-term and 1-year composite





(n ¼ 859) P value
Revascularization 29 (5.2%) 30 (3.5%) .13
Myocardial infarction 9 (1.6%) 15 (1.7%) >.999
Death 13 (2.3%) 25 (2.9%) .61
1-y Composite end point* 47 (8.5%) 62 (7.2%) .42
Data represent numbers of patients. *Primary 1-year composite end point was death
from any causewithin 1 year after surgery, myocardial infarction between 30 days and
1 year, or any revascularization procedure between 30 days and 1 year.
The Journal of Thoracic and Capoorer SVG patency and more frequent repeat revasculari-
zation. According to the sensitivity analysis performed,
moreover, this EVH versus OVH effect was not different
in the subgroup of high-volume EVH centers.
SVG patency was significantly lower in the EVH group
than in the OVH group for both off-pump and on-pump
CABG (data not shown). By multivariable analysis, the ef-
fect of EVH relative to OVH on graft patency appeared to be
independent of the effects of off-pump versus on-pump ap-
proach (that is, no greater combined effect observed for the
use of off-pump with EVH technique than seen when eval-
uating these effects in isolation). In addition, the higher re-
peat revascularization rate in the group of EVH patients
with 1-year catheterization data may be explained by the
higher rate of SVG occlusion driving percutaneous inter-
ventions at the time of angiography (Figure 2).
EVH commonly requires carbon dioxide to insufflate the
subcutaneous cavity and bipolar cautery in the vicinity of
SVGs, whereas neither insufflation nor bipolar energy is re-
quired for OVH. The use of cautery has been proposed to
cause thermal injury to the vessel wall, which may impair
the graft quality by compromising the viability of endothe-
lial cells, resulting in platelet aggregation and thrombosis.
Relatively longer manipulation times and the use of rigid
devices in EVH may also cause direct mechanical injury
to the SVGs. No study has addressed the effect of the use
of carbon dioxide insufflation (either carbon dioxide itself
or its gas pressure) on the quality of SVGs. Rousou and col-
leagues17 recently reported that relative to OVH, EVH ad-
versely affects vein endothelial function. This finding is
potentially important because endothelial dysfunction
would adversely affect the entire vein graft, whereas heat
or mechanical injuries would likely be localized.
It is also important to take into consideration the flow-
dynamic physics for graft patency. Disease severity in the
distal coronary artery, so-called runoff, is significantly asso-
ciated with graft patency. Specifically, poor runoff is associ-
ated with a high rate of graft occlusion.6,18 This factor was
not assessed in our study.
Our study has additional limitations. Because the vast
majority of ROOBY Trial patients were male, the conclu-
sions may not be applicable to female patients, althoughrdiovascular Surgery c Volume 141, Number 2 341
TABLE 7. Patency outcomes (n ¼ 894)
Endoscopic (no.) Open (no.) Absolute percentage difference (95% CI) Relative risk (95% CI) P value
Occluded SVG (1) 141/341 (41.3%) 155/553 (28.0%) 13.3 (6.9–19.8) 1.23 (1.11–1.36) <.0001
SVG patency* 513/689 (74.5%) 952/1118 (85.2%) 10.7 (6.8–14.6) 1.14 (1.09–1.20) <.0001
CI, Confidence interval; SVG, saphenous graft. *FitzGibbon grade A or B.
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Dfemale sex has not to our knowledge been identified as an
independent risk factor for graft failure. In addition, this
study did not randomize the assignment to the EVH or the
OVH technique. Confounders related to surgeon’s decision
to use an EVH approach for SVG harvest may therefore
have affected this study’s findings.
As a potential positive attribute, this ROOBY Trial sub-
study was a multicenter study with many surgeons and mid-
level providers with variable degrees of expertise. Thus the
results may be more representative of EVH practice than
single-center, ‘‘expert surgeon’’ or ‘‘expert midlevel pro-
vider’’ studies.
Although a few randomized studies comparing EVH and
OVH have been published, they suffer from low volumes of
patients, lack of angiographic assessment, or short follow-
up.7,19,20 In the EPIC (Evaluation of the PAS-Port in Coro-
nary Surgery) Trial, worse SVG angiographic patency at 9
months was seen with EVH than with OVH (79.2% vs
90.8%).21 A recent meta-analysis of 102 studies comparing
the EVH and OVH in CABG concluded that long-term graft
patencies in SVGs harvested by OVH were better than in
those harvested by EVH (pooled odds ratio 1.25,
P ¼ .0039).6 Our ROOBY Trial substudy supports the find-
ings from this meta-analysis, because the 1-year patencies
of SVGs harvested with EVH were lower than seen with
OVH, and EVH was associated with a higher rate of repeat
revascularization.
Considering that no specific guidelines (except for the
2005 International Society for Minimally Invasive Cardiac
Surgery’s consensus statement22) are currently available toFIGURE 2. Kaplan–Meier estimate of time to repeat revascularization
(n ¼ 894).
342 The Journal of Thoracic and Cardiovascular Surgassist the clinician in decision making regarding the SVG
harvest technique, the risks and benefits of EVH relative
to OVH need to be carefully addressed with the patient
and referring cardiologist on a case-by-case basis until
more definitive evidence becomes available. In addition,
further research may be required to find and support
methods of preventing graft failure, possibly including im-
plementation of a more intense perioperative antithrom-
botic regimen when using EVH.23,24 In light of the recent
meta-analysis and these ROOBY Trial findings, a large,
prospective, randomized study now appears warranted.
We are indebted to Janet H. Baltz, RN, Annette Wiseman,
Jennifer Carrick, RN, MS, CCRC, Jennifer M. Gabany, MSN,
CRNP-C, CCRC, and Timothy Miller, PA-C, for their invaluable
contributions to this study.References
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Dr Zenati, as you know very well, the ROOBY Trial concluded
that at 1-year follow-up, patients undergoing off-pump CABG had
worse composite outcomes and poorer graft patencies than those
undergoing on-pump CABG. More interestingly, in your study,
when EVH was compared with OVH, 1-year patency was signifi-
cantly lower and revascularization rate significantly higher for
EVH.
Despite the proven advantages of EVH relative to OVH in terms
of wound complications and cosmesis, your data incorporated in-
formation showing that 1-year graft patency might be compro-
mised with endoscopic harvesting. Previous studies that included
smaller populations and angiography performed within the first
6 postoperative months did not show differences in patency.
Your data support a nonrandomized study showing worse out-
comes with EVH, and generally speaking it appears that SVG fail-
ure is higher with EVH, as also shown in a recent meta-analysis. In
addition, your patient population seems to be a good representa-
tion of ‘‘real life,’’ at least on the male side.
Reduced graft patency with EVH could be related to intrao-
perative trauma, which is inherent in the technique. There isThe Journal of Thoracic and Caalso information suggesting that EVH may impair endothelial
function.
The eventual implications of your study, in combinationwith the
available information on graft patency related to the harvesting
technique, could have potential impact on clinical practice and per-
haps relegate EVH and its association with off-pump surgery to the
suboptimal side in terms of long-term results. Your study appears to
be sufficiently poweredwhen compared to previous studies to draw
meaningful conclusions, despite a number of limitations that you
clearly addressed in your presentation and also in your manuscript.
Finally, before proceeding with my questions, I obviously have
to thank you for this significant and controversial piece of informa-
tion and the opportunity for advanced manuscript review and the
Association for the privilege of the discussion.
I have basically 3 questions for you. First, do you have informa-
tion about which were the territories with the highest occlusion
rate? If so, did that have a clinical impact on your patients?
Dr Zenati. Thank you, DrMestres, for your kind comments and
your question. Regarding the distribution of the SVGs and relative
patency as related to the harvesting technique, the right coronary
distribution, interestingly enough, did not show any difference in
terms of patency whether the conduit harvest was endoscopic or
open. The patency was 87.5% for EVH and 85.6% for OVH.
The difference was not statistically significant. When we looked
at the diagonal and obtuse marginal coronary arteries, the patency
was significantly higher for both targets when the harvest was
open. Patency was 69.7% in the obtuse marginal branch with
EVH, versus 82.9% with OVH.
Dr Mestres. Second, considering that a limitation is that you
did not randomly assign the harvesting technique, I find some
differences with especially the PREVENT trial, because that was
organized in the early phases of the learning curve with harvesting
techniques, whereas your trial was, of course, more recent in terms
of chronology. So, would you suggest that going through the learn-
ing curve in harvesting on an endoscopic basis is not a major prob-
lem in this trial?
Dr Zenati. You raise the issue of experience with harvesting,
and our trial does cover a more recent period than did the PRE-
VENT subanalysis. As we saw, the penetration of EVH technique
in the United States at the beginning of the ROOBY Trial in 2002
was probably less than 10%, rising almost exponentially to about
76% in 2008.Wewere not able to account for the effect of the level
of experience or the volume of procedures performed by the prac-
titioner who harvested the SVGs, however, because these data
were not collected.
Dr Mestres. Third, what is your current antithrombotic ther-
apy? Also, assuming that EVH represents basically induced endo-
thelial trauma, do you think that a more intense antithrombotic
regimen would be of any help?
Dr Zenati. You raise a very important point about the perioper-
ative antithrombotic approach in relationship to the potential for
increased endothelial damage during the harvest. Aspirin use
was ubiquitous in this study, and about 30% of patients also
received clopidogrel. The CASCADE trial was just presented
last fall at the American Heart Association, however, and its results
were negative in terms of the ability of the dual antiplatelet to im-
prove graft patency. This is something we need to reassess, and po-
tentially we need to include consideration of pharmacogenomicsrdiovascular Surgery c Volume 141, Number 2 343
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Dto take into account low metabolizers when prescribing clopidog-
rel. On top of that, there is the issue of heparin at the beginning of
harvest, which has been shown in some series to affect graft
failure, but these data were not collected in this study and should
be in the future.
Dr Mestres. Thank you very much for this important contribu-
tion.
Dr Omar Lattouf (Atlanta, Ga). Dr Zenati, thank you for your
presentation. The points that you raise have significant medicole-
gal impact for those of us who use EVH. First, in defense of EVH, I
have to say that the data that you have presented did not take into
account any technical issues that were encountered at the time of
vein harvest either way and were not recorded. Second, we do344 The Journal of Thoracic and Cardiovascular Surgnot know the starting point for the conduit patency documented
by angiography, coronary ultrasonography, or flow patencies. If
you do have those data, can you share them with us, please?
Dr Zenati. Thank you. Regarding the technical issue, as I indi-
cated, a limitation of the study is that device-related or experience
issues may have affected outcomes, and these data unfortunately
were not collected, so I cannot comment on that. I believe that
future studies should consider device-related variables very seri-
ously, because the EVH technique is improving and evolving.
With respect to the timing of the failure of the grafts, most
(more than 90%) were protocol angiographies. So the graft could
have been closed at an earlier stage, and that is unfortunately
difficult to evaluate and comment on.ery c February 2011
